DaVita Target of Unusually High Options Trading (NYSE:DVA)

DaVita Inc. (NYSE:DVA) was the target of some unusual options trading on Friday. Stock traders acquired 11,404 call options on the company. This represents an increase of approximately 508% compared to the average daily volume of 1,875 call options.

Wall Street Analysts Forecast Growth

DVA has been the topic of several analyst reports. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Raymond James Financial set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Oppenheimer set a $220.00 target price on shares of DaVita in a report on Friday, August 7th. UBS Group increased their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Stock Performance

Shares of NYSE:DVA traded down $1.33 during midday trading on Friday, reaching $181.76. 156,183 shares of the company’s stock traded hands, compared to its average volume of 918,086. DaVita has a 1 year low of $101.00 and a 1 year high of $247.49. The company has a market cap of $11.60 billion, a P/E ratio of 14.85, a PEG ratio of 0.50 and a beta of 0.83. The company has a fifty day simple moving average of $200.58 and a two-hundred day simple moving average of $186.72.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same period in the prior year, the business posted $2.95 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts forecast that DaVita will post 14.57 EPS for the current fiscal year.

Institutional Trading of DaVita

Large investors have recently made changes to their positions in the company. Berkshire Hathaway Inc acquired a new stake in DaVita in the 2nd quarter valued at about $6,425,269,000. BlackRock Inc. acquired a new stake in DaVita in the second quarter valued at approximately $547,520,000. Bank of America Corp DE acquired a new stake in DaVita in the second quarter valued at approximately $145,057,000. Arrowstreet Capital Limited Partnership lifted its stake in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after acquiring an additional 636,191 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in DaVita during the 2nd quarter worth approximately $101,127,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.